by Lee Seungjin
Published 15 Feb.2024 18:09(KST)
On the 15th, FSN announced that it will acquire 41.42 million shares of Mediphron Divity, a pharmaceutical research and manufacturing company, for 42 billion KRW.
After the acquisition, FSN's stake in Mediphron Divity will be 44.5%. The scheduled date for the stock acquisition is April 30 of this year.
FSN stated that the purpose of this stock acquisition is "to expand business areas and enhance synergy with existing businesses."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.